P3 Health Partners (PIII) Stock Falls -35% in 30 Days Despite Q3 Earnings Beat

Key Takeaways

• P3 Health Partners shares fell roughly 35% over the last 30 days, sliding from about $4.03 to near $2.63, despite a headline-beating third-quarter earnings report.
• The sharp decline followed renewed concerns over higher medical costs, a shrinking at-risk membership base, and a reduced earnings-quality picture once one-time items are excluded.
• For the broader quarter, the stock has fallen approximately 77% from its mid-August level near $11.69, extending a multi-month downtrend.
• Analysts trimmed price targets after the report, with TD Cowen cutting its target to $4 from $13 and Lake Street lowering its target to $11.50 from $23.
• Q3 2026 revenue rose 15% year over year to $396.3 million, while adjusted EBITDA reached $21 million and full-year 2026 adjusted EBITDA guidance was raised to a $90–$110 million range.
• For more detail on Price Targets, Earnings, and Forecast data, explore the dedicated P3 Health Partners pages.
• To see how algorithmic strategies are positioning across the market, explore Trending AI Robots.

Company Overview and Market Position

P3 Health Partners is a patient-centered, physician-led population health management company based in Henderson, Nevada. The company partners with primary care physicians and community providers to coordinate care for Medicare Advantage and other value-based arrangements, with the goal of improving patient outcomes while lowering the total cost of care.

Its model spans care coordination, utilization management, claims processing, and quality improvement for assigned members. I follow PIII closely because its revenue and earnings are tied to membership growth, medical cost trends, and payer economics — all of which can swing results materially from quarter to quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, PIII shares have fallen approximately 35%, declining from a closing level of about $4.03 in mid-October to near $2.63. Much of that decline came immediately after the company's third-quarter report, when the stock fell sharply on elevated volume in two consecutive sessions.

The picture over the last quarter is even steeper. Roughly three months earlier, in mid-August, the stock was trading near $11.69, meaning shares have lost approximately 77% of their value over that span. This reflects a sustained downtrend that accelerated in the final stretch, rather than a single isolated event.

What Drove the Recent 30-Day Move

The most significant catalyst was the company's third-quarter 2026 earnings release on November 9. P3 reported revenue of $396.3 million, up 15% year over year, net income of $30.8 million, and diluted earnings per share of $0.07 — results that beat consensus expectations. Management also raised the midpoint of its full-year 2026 adjusted EBITDA guidance to $100 million, within a $90–$110 million range.

Despite the headline beat, the stock sold off sharply. Several factors explain the negative reaction. First, the quality of earnings drew scrutiny: roughly $12 million of the quarter's $21 million in adjusted EBITDA came from a favorable prior-period CMS ACO reconciliation and a non-cash liability release tied to an ACO joint venture, leaving underlying adjusted EBITDA closer to $10 million. Second, medical cost pressure persisted, with an adjusted medical loss ratio around 90.6% and medical claims expense near $322 million. Third, at-risk membership declined about 9% year over year to roughly 105,000 members.

Analyst actions compounded the decline, with price target reductions from multiple firms, and a previously filed S-3 registration statement in mid-October kept potential dilution in focus for investors. From what I see, these elements together explain much of the reaction.

Broader Quarterly Drivers

P3 Health Partners' decline over the last quarter has been broad-based. After trading in the $11–$12 range in mid-August, shares drifted lower through September and October as investors reassessed the company's near-term trajectory. The combination of a shrinking at-risk membership base, elevated medical costs, and questions around the sustainability of reported profitability weighed on sentiment.

While management has emphasized progress in utilization management, payer economics, and a path toward a multi-year value-creation opportunity, the market has focused on the durability of earnings and the balance-sheet and dilution considerations that accompany a small-cap value-based care operator.

What to Watch Next

Looking ahead, investors will be monitoring several key factors. First, the trajectory of the medical loss ratio and medical cost trends will be central, since cost containment is the primary driver of adjusted EBITDA in the value-based care model. Second, membership figures — including at-risk lives and total lives under management — will signal whether the company can stabilize or return to growth after deliberate portfolio pruning.

Additionally, updates to full-year guidance, any new capital raises or dilution events, analyst rating changes, and progress on the company's stated multi-year value-creation opportunity will all influence the stock. Broader regulatory and reimbursement developments in Medicare Advantage remain an ongoing industry-level risk to monitor. I’m watching this closely for signs of stabilization.

Exploring Algorithmic Perspectives

In my analysis, I often review data from Tickeron’s Trending AI Robots to understand how systematic strategies are positioned in names like PIII. This page highlights a curated selection of algorithmic trading bots drawn from a much larger universe of hundreds of bots that collectively trade thousands of tickers. Only the top-performing and most relevant strategies appear in this section, giving users a focused view of current market activity. The bots vary by strategy, timeframe, and performance metrics, so the page serves as a starting point for investors interested in data-driven, systematic approaches to trading. Exploring the section can help you identify patterns and strategies aligned with your own analytical goals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume